ֱ

OncoBreak: Waste of Talent; Anti-HPV Drug; Heating Prostate Cancer

— News, features, and commentary about cancer-related issues

MedpageToday

Combining a drug that shut off a tumor's blood supply with an immune checkpoint inhibitor stimulated growth of that enhanced the delivery of cancer-fighting immune cells to the tumor -- in preclinical studies. (Science Translational Medicine)

An oncologist-blogger laments the "waste of talent" resulting from the that occur each year in the United States. (ASCO Connection)

When it comes to genetic testing for , less might prove to be more. (JAMA Oncology)

Immunotherapy also played a prominent role in combination therapy that resulted in objective responses in as many as half of patients with . (University of Texas MD Anderson Cancer Center)

The American Society of Clinical Oncology adopted recommendations for improving the use of to guide clinical decision making in cancer. (ASCO)

A preliminary study of a plant-based therapy showed of human papillomavirus in patients with symptomatic and asymptomatic infection. (Drug Design, Development and Therapy)

Studies in mice identified a signaling pathway and two associated proteins that pancreatic cells produce to . (NYU Langone Medical Center)

Researchers found a potential "braking mechanism" that prostate tumors use to remain when immunotherapy tries to heat them up. (University of Texas MD Anderson Cancer Center)

The FDA granted for the PARP inhibitor olaparib (Lynparza) as maintenance therapy for relapsed, platinum-sensitive ovarian cancer. (AstraZeneca)

Exposure to may contribute to an increased risk of thyroid cancer. (Duke University Medical Center)

The FDA granted for palbociclib (Ibrance) to include first-line treatment of hormone receptor-positive/HER2-negative breast cancer. (Business Wire)

The agency also granted full approval to osimertinib (Tagrisso) for treatment of that progressed during or after treatment with an EGFR inhibitor. (FDA)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined ֱ in 2007.